PBMs make more money when a drug's list price increases, while patients bear the financial burden.
Editor's note · Context
Menendez highlights the conflict of interest in PBM pricing structures.
Share & report
More from Bob Menendez
For the record, Mr. Secretary, since my time has expired would you respond to that question for me, what are we doing to get the Solomon Islands to be aligned with us, particularly in our security partnership with Australia?
Mr. President, I come to the Senate floor to respond to a series of accusations raised by the U.S. attorney of the Southern District of New York. First, I would note that this is the second superseding indictment brought forth by the…
Without market access I think that we are going to be at a competitive disadvantage with China.
The urgency of climate change; there is a lot more that we should be doing as it relates to climate change.





